porosome reconstitution therapy

Porosome reconstitution therapy is a novel, cell-based therapeutic approach developed by Porosome Therapeutics. It involves the introduction of healthy, functional porosomes—cellular secretory machinery complexes—into the plasma membrane of diseased cells to restore or enhance their secretory function. The mechanism is based on replacing or supplementing defective or absent porosomes in target cells with functional ones extracted from healthy donor cells. This strategy has been applied to diseases characterized by secretory defects, such as cystic fibrosis (CF), diabetes (Type 1 and Type 2), and neurodegenerative disorders like Alzheimer’s disease. In cystic fibrosis, for example, the therapy introduces healthy porosomes containing functional CFTR protein into airway epithelial cells lacking proper CFTR function. This restores normal chloride ion flow and mucus secretion regardless of the underlying genetic mutation[2][3][4]. In diabetes, particularly for iPSC-derived beta cell replacement therapies in Type 1 Diabetes (T1D), reconstituting insulin-secreting porosomes into stem cell-derived beta cells enhances glucose-stimulated insulin secretion[1][5]. For Alzheimer’s disease and other neurodegenerative conditions, preclinical studies suggest that restoring neuronal secretory machinery via this method can improve neurotransmitter release and cellular metabolism[6]. The platform also enables precision targeting using nanobodies or small molecules to modulate undruggable proteins within the porosome complex.

Other names

porosome therapyporosome-based therapy